July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Real-world plaque brachytherapy clinical practices among Ocular Oncology Study Consortium treatment centers
Author Affiliations & Notes
  • prithvi Mruthyunjaya
    Byers Eye Institute, Palo Alto, California, United States
  • Christina Binder
    Radiation Oncology, Oregon Health Sciences, Portland, Oregon, United States
  • Amy C Schefler
    Retina Consultants of Houston, Houston, Texas, United States
    Houston Methodist Hospital, Blanton Eye Institute, Houston, Texas, United States
  • Michael Seider
    Permanent Group, San Francisco, California, United States
  • Alison Skalet
    Casey Eye Institute, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   prithvi Mruthyunjaya, None; Christina Binder, None; Amy Schefler, None; Michael Seider, None; Alison Skalet, None
  • Footnotes
    Support  Research to Prevent Blindness (PM)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3624. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      prithvi Mruthyunjaya, Christina Binder, Amy C Schefler, Michael Seider, Alison Skalet; Real-world plaque brachytherapy clinical practices among Ocular Oncology Study Consortium treatment centers. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3624.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Planning for I-125 plaque brachytherapy (PBT) for uveal melanoma has advanced in recent years, allowing for image-guided planning and improved dosimetry. In order to compare real-world treatment practices, this study reports PBT practice patterns at institutions from the Ocular Oncology Study Consortium (OOSC).

Methods : Information regarding brachytherapy clinical practices was obtained from the OOSC database and a treatment practice survey. The OOSC database contains information from 9 U.S. referral centers regarding tumor characteristics and treatment parameters for 428 subjects treated between 2010 and 2014. The survey queried treatment planning methods and prescriptions and was completed by 7 of the OOSC institutions

Results : The majority of institutions follow American Brachytherapy Society (ABS) and American Association of Physicists in Medicine guidelines with regard to dose and prescription point (Table 1). Actual dosimetry methodology varied between institutions with median apical dose of 85Gy and dose rate of 78cGy/hr. Safety margins generally adhered to the 2-3mm guideline but were larger in some cases, particularly for notched plaques or anterior tumors. 85% of institutions used pre-loaded plaques while all institutions now usePlaque Simulator (Eye Physics LLC, Los Angles, CA). Normal tissue constraints are not used at most institutions.

Conclusions : While there were differences in dosimetric practices, there was overall good agreement among PBT practices at the participating institutions including prescription dose, safety margins, and planning methodology. Although it is not FDA-approved, all institutions responding to the survey are now using the Plaque Simulator for treatment planning. However, dose-rates varied between institutions and in some cases fell outside of ABS guidelines. Improved planning technology may allow for more uniform dose calculations to normal structures and improved tumor dosimetry for entry into treatment trials to minimizing radiation toxicity. Further studies are required to refine uncertainties in planning and determine a minimally effective dose.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×